Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 5:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 29,092 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: dose level 1 Clear all
Terminated Phase 1 Interventional

Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

NCT00590603
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Arsenic Trioxide, Ascorbic Acid and Bortezomib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Nov 13, 2026, 5:42 AM EST
Completed Phase 1 Interventional Results available

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASP8062 With a Single Dose of Morphine in Recreational Opioid Using Participants

NCT04448561
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
ASP8082, morphine, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Nov 13, 2026, 5:42 AM EST
Not yet recruiting Phase 1Phase 2 Interventional

NANOVAE to Treat Knee Osteoarthritis (KOA)

NCT06606561
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
NANOVAE - Acellular Allogenic Human Amniotic Fluid (hAF), 0.9% Sodium Chloride Injection, USP
Drug
Lead sponsor
Nova Vita Laboratory
Industry
Eligibility
21 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 13, 2026, 5:42 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Trial of Randomized Antibiotic Administration in Percutaneous Nephrolithotomy

NCT02579161
View directory record Official record
Conditions
Kidney Stones
Interventions
cephalosporins, Fluoroquinolones, Clindamycin, Ampicillin/Gentamicin
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
2
States / cities
Manhasset, New York • New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Nov 13, 2026, 5:42 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers

NCT03856970
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Microgestin®, Levothyroxine, Glyburide, Digoxin, IW-3718
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Nov 13, 2026, 5:42 AM EST
Completed Phase 3 Interventional Results available

Lurasidone Pediatric Autism Study

NCT01911442
View directory record Official record
Conditions
Autism
Interventions
Lurasidone 20 mg daily, Lurasidone, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
41
States / cities
Dothan, Alabama • Phoenix, Arizona • Newport Beach, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Nov 13, 2026, 5:42 AM EST
Completed Phase 2 Interventional Results available

Temozolomide and Radiation Therapy in Treating Patients With Gliomas

NCT00114140
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
Temozolomide, Radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2022
U.S. locations
45
States / cities
Phoenix, Arizona • Los Angeles, California • Newark, Delaware + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Nov 13, 2026, 5:42 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating PRA-027 Multiple Ascending Doses In Cycling And Postmenopausal Women

NCT00543790
View directory record Official record
Conditions
Uterine Leiomyomata (Fibroids)
Interventions
PRA-027
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Beverly Hills, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 28, 2010 · Synced Nov 13, 2026, 5:42 AM EST
Completed Phase 3 Interventional Results available

Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00723190
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
CLONICEL (Clonidine HCl sustained release)
Drug
Lead sponsor
Shionogi
Industry
Eligibility
6 Years to 17 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
27
States / cities
Little Rock, Arkansas • El Centro, California • Irvine, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Nov 13, 2026, 5:42 AM EST
Completed Phase 4 Interventional Results available

Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant Recipients

NCT00121810
View directory record Official record
Conditions
Kidney Transplantation
Interventions
mycophenolate mofetil [CellCept], Corticosteroids, Calcineurin inhibitors, Sirolimus
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
36
States / cities
Bakersfield, California • Los Angeles, California • Palo Alto, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2011 · Synced Nov 13, 2026, 5:42 AM EST
Completed Phase 2 Interventional Results available

Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer

NCT01829113
View directory record Official record
Conditions
Non Squamous Non Small Cell Lung Cancer
Interventions
OGX-427, Placebo
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
16
States / cities
Denver, Colorado • Fort Myers, Florida • Orlando, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Nov 13, 2026, 5:42 AM EST
Completed Phase 3 Interventional Results available

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

NCT02585713
View directory record Official record
Conditions
Cerebral Vein Thrombosis, Deep Vein Thrombosis, Gonadal Thrombosis, Hepatic Thrombosis, Malignant Neoplasm, Mesenteric Thrombosis, Metastatic Malignant Neoplasm, Portal Vein Thrombosis, Pulmonary Embolism, Renal Vein Thrombosis, Splenic Thrombosis, Venous Thromboembolism
Interventions
Apixaban, Dalteparin, Questionnaire Administration
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
18
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Evanston, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Nov 13, 2026, 5:42 AM EST
Terminated Phase 1 Interventional Results available

First-in-Human Study of MS201408-0005A as Single Agent and in Combinations

NCT03306420
View directory record Official record
Conditions
Metastatic or Locally Advanced Unresectable Solid Tumors
Interventions
M4112
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
New Haven, Connecticut • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Nov 13, 2026, 5:42 AM EST
Completed Phase 3 Interventional Results available

Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma

NCT00075582
View directory record Official record
Conditions
Adult Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma, Embryonal-botryoid Childhood Rhabdomyosarcoma, Previously Untreated Childhood Rhabdomyosarcoma
Interventions
conventional surgery, dactinomycin, cyclophosphamide, vincristine sulfate, radiation therapy
Procedure · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 49 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2021
U.S. locations
138
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 113 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Nov 13, 2026, 5:42 AM EST
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)

NCT01225146
View directory record Official record
Conditions
Ischemia, Retinal Vein Occlusion, Pathologic Processes, Retinal Diseases, Eye Diseases
Interventions
ranibizumab
Drug
Lead sponsor
David M. Brown, M.D.
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Nov 13, 2026, 5:42 AM EST
Completed Phase 2 Interventional Results available

Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)

NCT02441803
View directory record Official record
Conditions
Leukemia
Interventions
Busulfan, Fludarabine, Clofarabine, Total Body Irradiation (TBI), Thymoglobulin, Stem Cell Infusion, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Decitabine, Cytarabine, Idarubicin
Drug · Radiation · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Nov 13, 2026, 5:42 AM EST
Completed Phase 3 Interventional Results available

Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes

NCT04707469
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Oral semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
84
States / cities
Buena Park, California • Fresno, California • La Mesa, California + 74 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Nov 13, 2026, 5:42 AM EST
Completed Phase 2 Interventional Results available

Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

NCT00425750
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
bortezomib, docetaxel, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
7
States / cities
Hopkinsville, Kentucky • Paducah, Kentucky • Crossville, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced Nov 13, 2026, 5:42 AM EST
Completed Phase 3 Interventional Results available

Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)

NCT01604850
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
SOF, RBV, Placebo to match SOF, Placebo to match RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
51
States / cities
Coronado, California • Los Angeles, California • San Diego, California + 41 more
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Nov 13, 2026, 5:42 AM EST
Completed Phase 3 Interventional Results available

LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

NCT01015118
View directory record Official record
Conditions
Ovarian Neoplasms, Peritoneal Neoplasms
Interventions
Placebo, Paclitaxel, BIBF 1120, Carboplatin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
33
States / cities
Tucson, Arizona • Long Beach, California • Santa Rosa, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Nov 13, 2026, 5:42 AM EST
Terminated Early Phase 1 Interventional Results available

Testosterone for Penile Rehabilitation After Radical Prostatectomy

NCT00848497
View directory record Official record
Conditions
Hypogonadism, Erectile Dysfunction
Interventions
Testim®, Placebo Testim®, Viagra®
Drug · Other
Lead sponsor
Mohit Khera
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2015 · Synced Nov 13, 2026, 5:42 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Dietary Fiber on Gastrointestinal Function

NCT01495182
View directory record Official record
Conditions
Gastrointestinal Health
Interventions
Dietary fiber
Other
Lead sponsor
Ingredion Incorporated
Industry
Eligibility
18 Years to 54 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Glen Ellyn, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Nov 13, 2026, 5:42 AM EST
Completed Phase 2 Interventional Results available

Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer

NCT00429182
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Carcinoma, Invasive Breast Carcinoma
Interventions
Carboplatin, Cyclophosphamide, Thiotepa, Stem Cell Transplant
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Nov 13, 2026, 5:42 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Seltorexant (JNJ-42847922) After Single-Dose Administration in Healthy Participants

NCT03682380
View directory record Official record
Conditions
Healthy
Interventions
Seltorexant High Dose, Seltorexant Low Dose
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Nov 13, 2026, 5:42 AM EST